APL-130277: Phase III started

Cynapsus began the double-blind, placebo-controlled, U.S. Phase III CTH-300 trial to evaluate 10, 15, 20, 25, 30 and 35 mg sublingual APL-130227 in about 126 levodopa-responsive patients who experienc...